MINNEAPOLIS, Jan. 6, 2011 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the manufacturer and marketer of minimally invasive Cooled ThermoTherapy™ (CTT), the durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), today announced that it will be presenting at the semi-annual Sidoti Micro-Cap Conference on Monday, January 10, 2011, at 11:20 a.m. Eastern Time. The event is being held at The Grand Hyatt Hotel, Park Avenue at Grand Central Station in New York City.
Mr. Stryker Warren jr., Chief Executive Officer, and Mr. Brian J. Smrdel, Chief Financial Officer, will present an overview of the Company's current business strategy and growth opportunities. They will also participate in a question and answer session following the presentation as well as one-on-one meetings throughout the day. The Company's presentation will be available on its website: .
For more information on the Sidoti Micro-Cap Conference, visit: .
Urologix, Inc., based in Minneapolis, develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders. The Company has developed and offers non-surgical, anesthesia-free, catheter-based treatments that use a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia, a condition that affects more than 23 million men worldwide. Urologix' products include the CoolWave® , Targis® and Prostatron® control units and the CTC Advance™, Cooled ThermoCath® , Targis® and Prostaprobe® catheter families. All of Urologix' products utilize Cooled ThermoTherapy™ - targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort - and provide safe, effective, lasting relief of the symptoms of BPH.
The Urologix, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7867
CONTACT: Brian J. Smrdel, Chief Financial Officer (763) 475-7696